Indian pharma firm Wockhardt said on Tuesday that it has received approval of the

RELATED ARTICLES Sun Pharma gets USFDA nod for nasal spray Aurobindo Pharma gets USFDA nod for generic anti-HIV drug Wockhardt Q4 net loss at Rs 191.64 cr Dr Reddy's, Sun Pharma get USFDA nod for heart disease drug Ind-Swift, Wockhardt launch generic Lipitor in UK

USFDA to sell a version of Pfizer’s anti-depressant drug Effexor’s extended release capsules.

The drug, Venlafaxine, used for treatment of depression and anxiety disorders, will be marketed in dosages of 37.5mg, 75mg and 150mg from June 1, the company said. According to IMS Health data, the total market for Effexor extended release capsules in the US market stood at $2.3 billion and is one of the most widely used anti-depressant drugs.

Wockhardt chairman Habil Khorakiwala said, “This is yet another successful demonstration of our capabilities in developing and making products based on extended release technologies. Our product selection strategies have revolved around maximising our strengths in this area of pharma technology and Venlafaxine XR bears testimony to the same.”